Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 688

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 2
Chunk 688
---
i) pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and disposition of the assets of the company; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the Company are being made only in accordance with authorization of management and
directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the Company’s assets that could have a material effect on the financial statements. During 2024, we designed
and implemented new and enhanced controls to strengthen our internal controls over financial reporting, including hiring additional experienced
accounting personnel, among other enhancements. Management believes these enhancements were sufficient to remediate previously identified
material weaknesses.

As of December 31, 2024, management
conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the framework established
in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission. Based
on the criteria established by COSO management concluded that the Company’s internal control over financial reporting was effective
as of December 31, 2024.

This Report does not include
an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting
as smaller reporting companies are not required to include such report and emerging growth companies (“EGC’s”) are exempt
from this requirement entirely until they are no longer an EGC. Management’s report is not subject to attestation by the Company’s
independent registered public accounting firm.

Changes
in Internal Control over Financial Reporting

There were no additional changes in our internal control over financial reporting (as defined in Rule
13(a)-15(f) of the Exchange Act) that occurred during the period covered by this annual report that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.

Item
9B. Other Information.

None.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not
applicable.

PART
III

Item
10. Directors, Executive Officers and Corporate Governance.

Our
directors and executive officers and their ages as of the date of this Report are as follows:

    Name

    Age
     
    Position
  
    Erez
    Aminov
     
    47